• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

Reminder - public consultation ends 30 September

This is a reminder that the EUCAST public consultation on carbapenem susceptibility testing and reporting ends on the 30 September, 2025: The proposed addition of a comment for carbapenemase-producing Enterobacterales. See also additional information in the Appendix. To respond to the consultation,…

Get to know more

Public consultations

Public consultation Public consultation is part of the EUCAST decision process. The consultation period is 4 - 12 weeks, and the dates of the beginning and end of the period is clearly stated. Previous public consultations with comments and EUCAST responses 2025 Archive Proposed new breakpoints for…

Get to know more

Public Consultations

Public Consultations Public consultation is part of the EUCAST decision process. The consultation period is 4 - 12 weeks, and the dates of the beginning and end of the period is clearly stated. Previous public consultations with comments and EUCAST responses 2025 2024 2023 Archive The (preliminary)…

Get to know more

TSU and TRI consultation finalised

Proposed revision of breakpoints for trimethoprim-sulfamethoxazole and trimethoprim. Public consultation 2025-05-07 - 2025-06-18. As a final result of each consultation, the comments obtained and the EUCAST Steering Committee rersponses are made public on the website. These are public comments and…

Get to know more

Public Consultations

Public Consultations Public consultation is part of the EUCAST decision process. The consultation period is 4 - 12 weeks, and the dates of the beginning and end of the period is clearly stated. Current public consultations Subject Dates Description Carbapenem susceptibility testing and reporting -…

Get to know more

Sitemap

Sitemap EUCAST - Home About EUCAST Organisation Steering Committee General Committee EUCAST Statutes National AST Committees (NAC) Network Laboratories Development Laboratories (EDL) Subcommittees Antimycobacterial Susceptibility Testing (AMST) Antifungal Susceptibility Testing (AFST) Veterinary…

Get to know more

EUCAST public consultation on breakpoints for intravenous use of fosfomycin.

EUCAST public consultation on breakpoints for intravenous use of fosfomycin . Consultation period 12 July - 12 September, 2023. The proposal has been revised following comments to the previous consultation and discussions with the EUCAST Steering Committee and stakeholders. Do not iterate comments…

Get to know more

Public consultation on Endocarditis breakpoints - EUCAST response

Following public consultation, EUCAST publishes formal responses to queries and views submitted during the consultation period. The comments during the consultation on EUCAST proposed endocarditis breakpoints , the EUCAST responses and decisions are now published (20 November, 2024). Throughout the…

Get to know more

Proposed change of breakpoints for aminopenicillins in enterococci

Proposed change of breakpoints for aminopenicillins in enterococci (consultation period 7 May - 14 June, 2024). Public consultation is part of the EUCAST decision process. The consultation period is 4 - 12 weeks, and the dates of the beginning and end of the period is clearly stated. Comments not…

Get to know more

Development of Clinical Breakpoints and ECOFFs

Development of Clinical Breakpoints and ECOFFs These pages collate information on the definition of clinical breakpoints and the process of setting MIC breakpoints. Background information is given in the Rationale Documents and in Public Consultations and the MIC:ZD (MIC vs. zone diameter)…

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here